
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
The Brief Psychiatric Rating Scale (BPRS) assesses the positive, negative, and affective symptoms of individuals with psychotic disorders.




